Axovant Sciences Ltd (AXON) Short Interest Down 31.3% in November

Axovant Sciences Ltd (NASDAQ:AXON) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 3,010,456 shares, a decrease of 31.3% from the November 15th total of 4,379,298 shares. Based on an average daily volume of 745,858 shares, the days-to-cover ratio is presently 4.0 days. Approximately 9.4% of the shares of the company are short sold.

Several equities analysts have recently commented on the company. Chardan Capital raised Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price for the company in a report on Wednesday. ValuEngine lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Axovant Sciences in a report on Wednesday, September 27th. Jefferies Group reissued a “buy” rating and issued a $12.00 price objective on shares of Axovant Sciences in a report on Wednesday, September 27th. Finally, JMP Securities reissued an “outperform” rating and issued a $19.00 price objective (down from $36.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $14.14.

Several large investors have recently made changes to their positions in AXON. FMR LLC lifted its position in shares of Axovant Sciences by 968.5% during the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after acquiring an additional 6,558,462 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Axovant Sciences during the 2nd quarter valued at $47,854,000. OxFORD Asset Management LLP lifted its position in shares of Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after acquiring an additional 777,505 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after acquiring an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Axovant Sciences during the 3rd quarter valued at $4,471,000. Institutional investors own 96.93% of the company’s stock.

Axovant Sciences (AXON) traded down $0.16 on Thursday, reaching $2.27. The company’s stock had a trading volume of 2,456,129 shares, compared to its average volume of 3,906,216. The firm has a market capitalization of $247.19 and a P/E ratio of -0.98. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. Axovant Sciences has a 12-month low of $2.23 and a 12-month high of $27.98.

WARNING: “Axovant Sciences Ltd (AXON) Short Interest Down 31.3% in November” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2018/01/11/axovant-sciences-ltd-axon-short-interest-update.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply